Platinum complexes in colorectal cancer and other solid tumors
(2021) In Cancers 13(9).- Abstract
Cisplatin is one of the most commonly used drugs for the treatment of various solid neoplasms, including testicular, lung, ovarian, head and neck, and bladder cancers. Unfortunately, the therapeutic efficacy of cisplatin against colorectal cancer is poor. Various mechanisms appear to contribute to cisplatin resistance in cancer cells, including reduced drug accumulation, enhanced drug detoxification, modulation of DNA repair mechanisms, and finally alterations in cisplatin DNA damage signaling preventing apoptosis in cancer cells. Regarding colorectal cancer, defects in mismatch repair and altered p53-mediated DNA damage signaling are the main factors controlling the resistance phenotype. In particular, p53 inactivation appears to be... (More)
Cisplatin is one of the most commonly used drugs for the treatment of various solid neoplasms, including testicular, lung, ovarian, head and neck, and bladder cancers. Unfortunately, the therapeutic efficacy of cisplatin against colorectal cancer is poor. Various mechanisms appear to contribute to cisplatin resistance in cancer cells, including reduced drug accumulation, enhanced drug detoxification, modulation of DNA repair mechanisms, and finally alterations in cisplatin DNA damage signaling preventing apoptosis in cancer cells. Regarding colorectal cancer, defects in mismatch repair and altered p53-mediated DNA damage signaling are the main factors controlling the resistance phenotype. In particular, p53 inactivation appears to be associated with chemoresis-tance and poor prognosis. To overcome resistance in cancers, several strategies can be envisaged. Improved cisplatin analogues, which retain activity in resistant cancer, might be applied. Targeting p53-mediated DNA damage signaling provides another therapeutic strategy to circumvent cisplatin resistance. This review provides an overview on the DNA repair pathways involved in the processing of cisplatin damage and will describe signal transduction from cisplatin DNA lesions, with special attention given to colorectal cancer cells. Furthermore, examples for improved platinum compounds and biochemical modulators of cisplatin DNA damage signaling will be presented in the context of colon cancer therapy.
(Less)
- author
- Köberle, Beate and Schoch, Sarah LU
- organization
- publishing date
- 2021-05-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Colorectal cancer, Mismatch repair defect, P53 signaling, Platinum drugs
- in
- Cancers
- volume
- 13
- issue
- 9
- article number
- 2073
- publisher
- MDPI AG
- external identifiers
-
- scopus:85104524855
- pmid:33922989
- ISSN
- 2072-6694
- DOI
- 10.3390/cancers13092073
- language
- English
- LU publication?
- yes
- id
- 28410078-8243-449e-81e3-1605d8367a53
- date added to LUP
- 2021-05-11 12:59:27
- date last changed
- 2024-06-16 13:35:17
@article{28410078-8243-449e-81e3-1605d8367a53,
abstract = {{<p>Cisplatin is one of the most commonly used drugs for the treatment of various solid neoplasms, including testicular, lung, ovarian, head and neck, and bladder cancers. Unfortunately, the therapeutic efficacy of cisplatin against colorectal cancer is poor. Various mechanisms appear to contribute to cisplatin resistance in cancer cells, including reduced drug accumulation, enhanced drug detoxification, modulation of DNA repair mechanisms, and finally alterations in cisplatin DNA damage signaling preventing apoptosis in cancer cells. Regarding colorectal cancer, defects in mismatch repair and altered p53-mediated DNA damage signaling are the main factors controlling the resistance phenotype. In particular, p53 inactivation appears to be associated with chemoresis-tance and poor prognosis. To overcome resistance in cancers, several strategies can be envisaged. Improved cisplatin analogues, which retain activity in resistant cancer, might be applied. Targeting p53-mediated DNA damage signaling provides another therapeutic strategy to circumvent cisplatin resistance. This review provides an overview on the DNA repair pathways involved in the processing of cisplatin damage and will describe signal transduction from cisplatin DNA lesions, with special attention given to colorectal cancer cells. Furthermore, examples for improved platinum compounds and biochemical modulators of cisplatin DNA damage signaling will be presented in the context of colon cancer therapy.</p>}},
author = {{Köberle, Beate and Schoch, Sarah}},
issn = {{2072-6694}},
keywords = {{Colorectal cancer; Mismatch repair defect; P53 signaling; Platinum drugs}},
language = {{eng}},
month = {{05}},
number = {{9}},
publisher = {{MDPI AG}},
series = {{Cancers}},
title = {{Platinum complexes in colorectal cancer and other solid tumors}},
url = {{http://dx.doi.org/10.3390/cancers13092073}},
doi = {{10.3390/cancers13092073}},
volume = {{13}},
year = {{2021}},
}